Eplerenone in patients with acute myocardial infarction complicated by heart failure.
نویسنده
چکیده
Eplerenone in Patients With Acute Myocardial Infarction Complicated by Heart Failure To the Editor: Pitt et al1 have concluded in their study that eplerenone should be prescribed to all of the postacute myocardial infarction patients with reduced left ventricular ejection fraction and heart failure. However, there are a few concerns in using eplerenone in certain populations. During the development of heart failure, there is an activation of the renin-angiotensin-aldosterone system. This leads to the use of angiotensin-converting enzyme inhibitors as a core treatment modality for heart failure. In the late 1990s, the Randomized Aldactone Evaluation Study showed that the aldosterone receptor antagonist spironolactone decreased rehospitalization attributable to heart failure by 35%.2 The same authors noted reduced cardiovascular mortality in postmyocardial infarction patients when using eplerenone in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study.3 These studies increased the prescription of aldosterone receptor antagonists and led to an increase in the incidence of hospitalizations attributable to hyperkalemia, especially in the elderly.4 This was particularly seen in patients with left ventricular ejection fraction 20%, on potassium supplements and concomitant usage of diuretics, along with lack of renal function monitoring. These episodes are also more frequent in patients with creatinine clearance 50 mL/min. In the United States, 7.5 million elderly patients have creatinine clearance 60 mL/min. Renal function calculated using serum creatinine is misleading in elderly because of their decreased muscle mass. This is clearly evident in one of the reviews that actually showed a calculated glomular filtration rate of 30 mL/min in patients with a baseline creatinine 1.8, who were prescribed aldosterone receptor antagonists.5 Therefore, the important message pertaining to elderly postmyocardial infarction patients is that glomular filtration rate should be calculated before treating with eplerenone, because the drug may do more harm than benefit if not selectively prescribed.
منابع مشابه
Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
BACKGROUND Aldosterone blockade is recommended for patients with congestive heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction; however, the perceived risk of hyperkalemia may limit implementation of this therapeutic approach. This subanalysis examined the relationship between eplerenone, serum potassium (K(+)), and clinical outcomes in the Eple...
متن کاملExtracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
BACKGROUND Aldosterone stimulates cardiac collagen synthesis. Circulating biomarkers of collagen turnover provide a useful tool for the assessment of cardiac remodeling in patients with congestive heart failure and left ventricular systolic dysfunction after acute myocardial infarction. METHODS AND RESULTS In a substudy of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy...
متن کاملHistory of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure.
In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (n=6632), eplerenone-associated reduction in all-cause mortality was significantly greater in those with a history of hypertension (Hx-HTN). There were 4007 patients with Hx-HTN (eplerenone: n=1983) and 2625 patients without Hx-HTN (eplerenone: n=1336). Propensity scores for eplerenone use, separately c...
متن کاملCost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
BACKGROUND In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), aldosterone blockade with eplerenone decreased mortality in patients with left ventricular systolic dysfunction and heart failure after acute myocardial infarction. The present study was performed to evaluate the cost-effectiveness of eplerenone compared with placebo in these patie...
متن کاملEplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
BACKGROUND Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure. We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure. METHODS Patients were rando...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Hypertension
دوره 52 6 شماره
صفحات -
تاریخ انتشار 2008